Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RLAY, ELVN, ALKS, COGT, AMLX, and represent 45.71% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: TNGX (+$70M), EDIT (+$29M), EYPT (+$25M), IFRX (+$16M), ASMB (+$11M), AVTX (+$9.9M), COGT (+$6.3M), RLMD (+$5.5M), Research Alliance Corp Iii (+$5.4M), ANTX.
- Started 5 new stock positions in VTGN, Research Alliance Corp Iii, EDIT, TNGX, IFRX.
- Reduced shares in these 10 stocks: SYRE (-$95M), RLAY (-$94M), NUVL (-$91M), ALKS (-$63M), KYMR (-$57M), ERAS (-$51M), CLDX (-$50M), XENE (-$48M), NRIX (-$35M), CRVS (-$33M).
- Sold out of its positions in CRVS, ERAS, KPTI, NRIX, OCUL, PALI, Soleno Therapeutics, XENE.
- Commodore Capital was a net seller of stock by $-543M.
- Commodore Capital has $1.7B in assets under management (AUM), dropping by -2.86%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 33 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relay Therapeutics (RLAY) | 13.4 | $225M | -29% | 12M | 18.71 |
|
| Enliven Therapeutics (ELVN) | 9.9 | $166M | 3.3M | 50.75 |
|
|
| Alkermes SHS (ALKS) | 9.4 | $157M | -28% | 3.0M | 52.40 |
|
| Cogent Biosciences (COGT) | 7.0 | $118M | +5% | 3.1M | 38.70 |
|
| Amylyx Pharmaceuticals (AMLX) | 6.0 | $102M | 5.7M | 17.96 |
|
|
| Definium Therapeutics Com Shs (DFTX) | 5.6 | $94M | 2.0M | 47.04 |
|
|
| Spyre Therapeutics Com New (SYRE) | 4.5 | $75M | -55% | 847k | 88.78 |
|
| Alto Neuroscience Com Shs (ANRO) | 4.3 | $72M | 2.7M | 26.39 |
|
|
| Tango Therapeutics (TNGX) | 4.2 | $70M | NEW | 2.3M | 31.26 |
|
| Eyepoint Com New (EYPT) | 3.9 | $66M | +62% | 4.6M | 14.30 |
|
| Tyra Biosciences (TYRA) | 3.6 | $60M | -24% | 1.9M | 31.94 |
|
| Damora Therapeutics Com New (DMRA) | 3.0 | $50M | 1.9M | 26.01 |
|
|
| Celldex Therapeutics Com New (CLDX) | 3.0 | $50M | -49% | 1.4M | 37.21 |
|
| Pharvaris N V (PHVS) | 2.9 | $49M | -25% | 1.4M | 34.58 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 2.9 | $49M | 1.5M | 32.45 |
|
|
| Assembly Biosciences Com New (ASMB) | 2.3 | $39M | +41% | 1.4M | 27.48 |
|
| Editas Medicine (EDIT) | 1.7 | $29M | NEW | 8.9M | 3.24 |
|
| Kymera Therapeutics (KYMR) | 1.7 | $29M | -66% | 250k | 114.67 |
|
| Perspective Therapeutics Com New (CATX) | 1.3 | $22M | 6.3M | 3.41 |
|
|
| Century Therapeutics (IPSC) | 1.3 | $21M | 8.7M | 2.45 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 1.1 | $19M | 3.3M | 5.90 |
|
|
| Avalo Therapeutics Com New (AVTX) | 1.1 | $19M | +110% | 1.0M | 18.48 |
|
| Inflarx Nv (IFRX) | 1.0 | $16M | NEW | 7.3M | 2.24 |
|
| An2 Therapeutics (ANTX) | 0.8 | $14M | +25% | 2.9M | 4.84 |
|
| Nuvalent Inc-a (NUVL) | 0.7 | $12M | -88% | 100k | 123.50 |
|
| Sab Biotherapeutics Com New (SABS) | 0.7 | $11M | -34% | 2.9M | 3.90 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.7 | $11M | 5.4M | 2.03 |
|
|
| Relmada Therapeutics (RLMD) | 0.6 | $9.9M | +124% | 1.4M | 6.92 |
|
| Pepgen (PEPG) | 0.5 | $8.1M | 4.5M | 1.80 |
|
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.3 | $5.4M | NEW | 500k | 10.70 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 0.3 | $5.3M | 500k | 10.64 |
|
|
| Athira Pharma (LONA) | 0.3 | $4.3M | 464k | 9.19 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.0 | $630k | NEW | 2.8M | 0.23 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2026 Q2 filed Aug. 14, 2026
- Commodore Capital 2026 Q1 filed May 15, 2026
- Commodore Capital 2025 Q4 filed Feb. 17, 2026
- Commodore Capital 2025 Q3 filed Nov. 14, 2025
- Commodore Capital 2025 Q2 filed Aug. 14, 2025
- Commodore Capital 2025 Q1 filed May 15, 2025
- Commodore Capital 2024 Q4 filed Feb. 14, 2025
- Commodore Capital 2024 Q3 filed Nov. 14, 2024
- Commodore Capital 2024 Q2 filed Aug. 14, 2024
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023